// App-Quantinova.ai

291 : Complement Activating Anti-HLA Antibodies: Identification of Specific Histo-Mmolecular Phenotype of Rejection for Complement-Targeting Therapy.

Researchers

Presenter

  • C. Lefaucheur

Principal Investigators

  • B. Sis

  • D. Viglietti

  • L. Hidalgo

  • O. Aubert

  • D. Glotz

  • C. Legendre

  • A. Zeevi

  • P. Halloran

  • A. Loupy

Medical Centers

  • Paris Translational Research Center for organ Transplantation, Paris, France

  • University of Pittsburgh Medical Center, Pittsburgh, PA

Locations

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Natural Killer cells

  • C-C Motif Chemokine Ligand 4

Drug/Treatment

  • Interferon Gamma

  • Eculizumab

  • Interferon

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved